A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs

Trial Identifier: D5551R00015
Sponsor: AstraZeneca
NCTID:: NCT05663515
Start Date: January 2024
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Pancreatic Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.